Oncorus to build viral immunotherapy production facility in Mass.
Clinical stage biopharmaceutical company Oncorus has signed a 15-year lease to build an 88,000-sq-ft good manufacturing practice (GMP) facility in Andover, MA.
The facility will manufacture viral immunotherapies for multiple cancer indications as part of Oncorus's efforts to advance its portfolio of cancer immunotherapies. The therapies will be administered intratumorally and intravenously and are based on the firm's oncolytic herpes simplex virus (oHSV) platform and synthetic virus platform.
Oncorus intends for the facility to provide a solution for its development needs, including performing manufacturing, quality, and supply of viral immunotherapies for investigational new drug studies. Oncorus is in the midst of conducting a phase I clinical trial for its lead product candidate, ONCR-177, and the firm has plans to nominate its first intravenous candidates as well as a second intratumoral candidate for brain cancer later this year.
The facility is expected to be completed in late 2021 and to achieve full operation, including multiproduct GMP manufacturing capabilities, in 2023. Oncorus also plans to continue partnering with contract manufacturing organizations for additional capacity and support.
January 4, 2021
https://www.scienceboard.net/
